ArticleBreast cancer research : BCR2026
O-GlcNAcylation regulates the DNA damage repair function of MND1 in breast cancer.
Article in Breast cancer research : BCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- O-GlcNAcylation at the tumor-immune interface: a metabolic post-translational code driving immune evasion and therapy resistance in cancer.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
introductionAs a meiosis-specific gene, Meiotic Nuclear Divisions 1 (MND1) plays a crucial role in homologous recombination and is generally silenced in somatic cells. The expression pattern and functional significance of MND1 in breast cancer (BRCA) have not been elucidated. This study systematically investigated the expression, subcellular localization, and pathological function of MND1 in BRCA, with particular focus on the post-translational regulation of MND1 through O-GlcNAcylation (O-GlcNAc) and its underlying molecular mechanisms.
methodsImmunohistochemical analysis and subcellular fractionation assays were performed to quantify MND1 expression levels and determine its intracellular localization in BRCA tissues and matched adjacent normal tissues. A drug-induced double-strand break (DSB) model combined with pH2A.X quantification were used to establish the functional correlation between MND1 and DSB repair efficiency. An in situ transplantation model of BRCA was established to evaluate the tumorigenic potential of MND1. O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) inhibitors, supplemented with site-directed mutagenesis (T121A mutation), were implemented to dissect the regulatory effects of O-GlcNAc on MND1 protein dynamics and functional competence.
resultsMND1 was aberrantly overexpressed and predominantly localized in the nucleus in BRCA cells. The DSB levels induced by DOX in BRCA cells were negatively correlated with the protein levels of MND1. knockdown of MND1 significantly inhibited tumor growth in mice, elevated the DSB levels, and reduced Ki67 levels in tumors. Immunoprecipitation coupled with in vitro glycosylation assays confirmed site-specific O-GlcNAc modification at MND1-T121. Pharmacological inhibition of OGT and T121A mutagenesis dramatically reduced MND1 protein stability and impaired nuclear localization. T121A mutation compromised MND1-mediated DSB repair capacity, resulting in persistently elevated pH2A.X levels. Inhibition of O-GlcNAc on MND1-T121 augmented MND1-HOP2 interaction, which led to a significant structural perturbation between the MND1-HOP2 complex.
conclusionsOur findings elucidate nuclear MND1 as a BRCA-specific HR activator stabilized by O-GlcNAc-mediated ubiquitination resistance. Thr121 O-GlcNAcylation facilitates MND1 nuclear retention and modulates HOP2 interaction dynamics, critically enabling HR-mediated repair. Loss of this modification disrupts repair fidelity, exposing a targetable vulnerability in BRCA. Future studies should characterize the structural basis of O-GlcNAc-dependent MND1-HOP2 regulation and its therapeutic implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.